Women's Studies

A5316 - Evaluating PK Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy

  • Question: Open label PK analysis of interactions between NuvaRing and Efavirenz or Atazanavir/r
  • Population: HIV-infected, non-pregnant women over 16 years of age, interested in using NuvaRing, that are on Atazanvir/r plus TDF and 1 or more other NRTI's that OR Efavirenz plus 2 or more NRTI's OR no ARV's 
  • Medication: ARV's are not provided. Participant is given on NuvaRing, with an optional additional NuvaRing at the end of study
  • Duration: Screening period up to 60 days, and 4 weeks on study. Visits include screen, entry, weeks 1, 2, 3, and 4
  • Call: Erin Hoffman919-843-0720 or Miriam Chicurel-Bayard 919-843-9922